Company profile
BRIDGEBIO PHARMA, INC.
NASDAQ:BBIOBiotechnology: Pharmaceutical Preparations
Drug pipeline (5)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ATTRUBY | approved | $222.4MQ2 2026 | 0 | — |
| ACORAMIDIS | phase4 | — | 11 | active |
| INFIGRATINIB | phase2 | — | 14 | active |
| BBP-398 | phase1_2 | — | 3 | terminated |
| BBO-8520 | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (33)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04836494 | phase1 | terminated | 2021-03-25 | 2023-11-20 | CoA Therapeutics, Inc., a BridgeBio company | A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia |
| NCT02150967 | phase2 | terminated | 2014-07-23 | 2021-03-01 | QED Therapeutics, a BridgeBio company | A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma |
| NCT04769479 | phase1 | completed | 2021-03-28 | 2021-08-04 | Eidos Therapeutics, a BridgeBio company | A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects |
| NCT04876924 | phase1 | completed | 2021-04-29 | 2022-02-27 | Cantero Therapeutics, a BridgeBio company | A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers |
| NCT06164951 | phase3 | completed | 2023-11-10 | 2025-12-18 | QED Therapeutics, a BridgeBio company | A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 216540 | 2024-11-22 | NDA | BRIDGEBIO PHARMA INC | |||||
Loading… | ||||||||